Voretigene Neparvovec-rzyl (Luxturna™)

Covered: one-time bilateral Luxturna (two subretinal injections) for patients with confirmed biallelic RPE65 mutation–associated retinal dystrophy who are 1 to <65 years old and have not previously received Luxturna (retreatment excluded). Key requirements: documentation of genetic confirmation of mutations in BOTH RPE65 alleles, clinician confirmation of viable retinal cells, administration by a retinal specialist at the recommended dose (1.5×10^11 vg/eye in 0.3 mL) on separate days ≥6 days apart, plus procedure, age, and treatment-history records.

"Luxturna is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy."

Sign up to see full coverage criteria, indications, and limitations.